Two companion studies published in Cancer Research by scientists at Moffitt Cancer Center identify distinct but complementary ...

Scientists have found a new way to stop cancer growth without damaging healthy cells. Researchers from the Francis Crick ...

We are gratified the FDA has granted Orphan Drug Designation to daraxonrasib for the treatment of pancreatic cancer, a devastating disease with limited therapeutic options and representing a large ...

Daraxonrasib received FDA orphan drug designation for pancreatic cancer, targeting RAS mutations in pancreatic ductal ...

The RAS family commonly drives the growth and survival of human cancers. Mutations in KRAS, NRAS, and HRAS occur in approximately 20% of all human cancers, including solid tumors, such as pancreatic, ...

Session Date/Time : Friday, December 12, from 12:30 p.m. – 2:00 p.m. CT ...

Circulating tumor DNA (ctDNA) is a promising biomarker for monitoring treatment response and progression-free survival in ...

Two companion studies published in Cancer Research from scientists at Moffitt Cancer Center identify distinct but complementary approaches to ...

Scientists at the Francis Crick Institute have developed a new cancer therapy that halts tumour growth without harming healthy cells, now entering human trials.

Cardiff Oncology's onvansertib's unique PLK1 inhibition mechanism offers breakthrough potential in multi-billion-dollar ...